3-iodobenzylguanidine has been researched along with Degenerative Diseases, Central Nervous System in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Annesi, G; Arabia, G; Ferini-Strambi, L; Gagliardi, M; Nistico, R; Novellino, F; Quattrone, A; Salsone, M | 1 |
| Bianconi, F; Marongiu, A; Nuvoli, S; Palumbo, B; Spanu, A | 1 |
| Blanc, F; Bousiges, O | 1 |
| Akamatsu, W; Fujimaki, M; Hattori, N; Imamichi, Y; Iseki, T; Kamagata, K; Kataura, T; Matsumoto, H; Miyamoto, K; Saiki, S; Sasazawa, Y; Shiina, K; Suzuki, A; Ueno, SI; Yamashita, Y | 1 |
| Nakamura, T; Orimo, S; Suzuki, M; Watanabe, H; Yogo, M | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Shang, J; Yamashita, T | 1 |
| Camacho, V; Carrio, I; Estorch, M; Flotats, A; Kulisevsky, J; Paredes, P; Rivera, E; Rodríguez-Revuelto, A | 1 |
| Hirata, K; Iwanami, M; Miyamoto, M; Miyamoto, T; Nishibayashi, M; Suzuki, K | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kametaka, S; Kurata, T; Manabe, Y; Morimoto, N; Ohta, T; Ohta, Y; Sato, S; Takao, Y | 1 |
| Inaba, A; Mizusawa, H; Orimo, S; Suzuki, M | 1 |
| Cason, E; Treglia, G | 1 |
| Artigas, C; Camacho, V; Carrió, I; Deportos, J; Domènech, A; Duch, J; Estorch, M; Fernández, A; Flotats, A; Geraldo, LL; Lleó, A; Marquié, M | 1 |
| Hattori, H; Nakade, S; Orimo, S; Ozawa, E; Takahashi, A; Taki, K; Tsuchiya, K | 1 |
| Taki, J; Tonami, N; Yamada, M; Yoshita, M | 1 |
| Amino, T; Itoh, Y; Kojo, T; Mori, F; Orimo, S; Takahashi, A; Takahashi, H; Tsuchiya, K; Uchihara, T; Wakabayashi, K | 1 |
| Yoshita, M | 1 |
| Braune, S | 1 |
5 review(s) available for 3-iodobenzylguanidine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease.
Topics: 3-Iodobenzylguanidine; Alzheimer Disease; Biomarkers; Diagnosis, Differential; Humans; Lewy Body Disease; Neurodegenerative Diseases; Tomography, Emission-Computed, Single-Photon | 2022 |
(123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies.
Topics: 3-Iodobenzylguanidine; alpha-Synuclein; Animals; Biomarkers; Heart; Humans; Neurodegenerative Diseases; Radionuclide Imaging; Radiopharmaceuticals | 2016 |
123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.
Topics: 3-Iodobenzylguanidine; Aged; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Neurodegenerative Diseases; Parkinson Disease; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity | 2012 |
Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease.
Topics: 3-Iodobenzylguanidine; Animals; Autonomic Nervous System; Brain; Clinical Trials as Topic; Humans; Lewy Body Disease; Neurodegenerative Diseases; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals | 2004 |
The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.
Topics: 3-Iodobenzylguanidine; Animals; Diagnosis, Differential; Humans; Multiple System Atrophy; Myocardium; Neurodegenerative Diseases; Parkinsonian Disorders; Radiopharmaceuticals | 2001 |
12 other study(ies) available for 3-iodobenzylguanidine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Aceruloplasminemia: a multimodal imaging study in an Italian family with a novel mutation.
Topics: 3-Iodobenzylguanidine; Ceruloplasmin; Humans; Iron Metabolism Disorders; Magnetic Resonance Imaging; Multimodal Imaging; Mutation; Neurodegenerative Diseases; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
123I-MIBG Cardiac Scintigraphy and Heart/Mediastinum Ratio in Neurodegenerative Disorders: Is Delayed Scan Really Necessary?
Topics: 3-Iodobenzylguanidine; Heart; Humans; Lewy Body Disease; Mediastinum; Neurodegenerative Diseases; Radionuclide Imaging; Radiopharmaceuticals | 2022 |
Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD.
Topics: 3-Iodobenzylguanidine; Heart; Humans; Liver; Neurodegenerative Diseases; Parkinson Disease; PPAR alpha; Radiopharmaceuticals | 2023 |
Peripheral arterial endothelial dysfunction of neurodegenerative diseases.
Topics: 3-Iodobenzylguanidine; Aged; Arteries; Biomarkers; Blood Chemical Analysis; Case-Control Studies; Endothelium; Female; Humans; Hyperemia; Male; Manometry; Neurodegenerative Diseases; Peripheral Arterial Disease; Radionuclide Imaging; Radiopharmaceuticals; Regression Analysis; Retrospective Studies; Severity of Illness Index | 2016 |
Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Cognition Disorders; Diagnosis, Differential; Early Diagnosis; Female; Follow-Up Studies; Heart; Humans; Iodine Radioisotopes; Lewy Body Disease; Male; Middle Aged; Neurodegenerative Diseases; Reproducibility of Results; Time Factors | 2008 |
123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder.
Topics: 3-Iodobenzylguanidine; Aged; Cross-Sectional Studies; Diagnosis, Differential; Female; Heart; Humans; Lewy Body Disease; Male; Mediastinum; Middle Aged; Multiple System Atrophy; Neurodegenerative Diseases; Parkinson Disease; Polysomnography; Radionuclide Imaging; REM Sleep Behavior Disorder; Supranuclear Palsy, Progressive | 2008 |
PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Basal Ganglia; Cerebral Cortex; Cerebrovascular Circulation; Cysteine; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Neurodegenerative Diseases; Organotechnetium Compounds; Parkinson Disease; Parkinsonian Disorders; Radiopharmaceuticals; Supranuclear Palsy, Progressive; Tomography, Emission-Computed, Single-Photon | 2011 |
Meta-analysis on MIBG scintigraphy in differential diagnosis between Parkinson's disease and neurodegenerative parkinsonism.
Topics: 3-Iodobenzylguanidine; Female; Humans; Male; Myocardial Perfusion Imaging; Neurodegenerative Diseases; Parkinson Disease; Radiopharmaceuticals | 2012 |
[Utility of early imaging of myocardial innervation scintigraphy in the diagnosis of Lewy Body Dementia].
Topics: 3-Iodobenzylguanidine; Aged; Cardiac Imaging Techniques; Cognition Disorders; Diagnosis, Differential; Female; Heart; Humans; Iodine Radioisotopes; Lewy Body Disease; Male; Neurodegenerative Diseases; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Time Factors | 2013 |
[123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Basal Ganglia; Cerebral Cortex; Diagnosis, Differential; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2003 |
Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Female; Ganglia, Sympathetic; Heart; Humans; Immunohistochemistry; Lewy Body Disease; Male; Middle Aged; Myocardium; Neurodegenerative Diseases; Neurons; Tyrosine 3-Monooxygenase | 2005 |
Loss of 123I-metaiodobenzylguanidine uptake by the heart in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Heart; Humans; Neurodegenerative Diseases; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals | 2000 |